These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 15662091

  • 1. Effect of simvastatin and fluvastatin on plasma fibrinogen levels in patients with primary hypercholesterolemia.
    Okopień B, Krysiak R, Madej A, Belowski D, Zieliński M, Kowalski J, Herman ZS.
    Pol J Pharmacol; 2004; 56(6):781-7. PubMed ID: 15662091
    [Abstract] [Full Text] [Related]

  • 2. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 3. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [Abstract] [Full Text] [Related]

  • 4. Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients.
    Faltaos DW, Urien S, Carreau V, Chauvenet M, Hulot JS, Giral P, Bruckert E, Lechat P.
    Fundam Clin Pharmacol; 2006 Jun; 20(3):321-30. PubMed ID: 16671968
    [Abstract] [Full Text] [Related]

  • 5. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L, Shah A, Davies MJ, Rotonda J, Maccubbin D, Tribble D, Veltri E, Mitchel Y.
    Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
    [Abstract] [Full Text] [Related]

  • 6. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S, Schuster H, Barter P, Watkins C, Kallend D, MERCURY I Study Group.
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [Abstract] [Full Text] [Related]

  • 7. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.
    Masana L, Mata P, Gagné C, Sirah W, Cho M, Johnson-Levonas AO, Meehan A, Troxell JK, Gumbiner B, Ezetimibe Study Group.
    Clin Ther; 2005 Feb; 27(2):174-84. PubMed ID: 15811480
    [Abstract] [Full Text] [Related]

  • 8. Fluvastatin prevents renal injury and expression of lactin-like oxidized low-density lipoprotein receptor-1 in rabbits with hypercholesterolemia.
    Yu YH, Wang Y, Dong B, Sun SZ, Chen Y, Meng XH, Liu ZZ.
    Chin Med J (Engl); 2005 Apr 20; 118(8):621-6. PubMed ID: 15899115
    [Abstract] [Full Text] [Related]

  • 9. Plasma lipids and blood fluidity in patients with polygenic hypercholesterolaemia treated with fluvastatin.
    Piñon F, Merino JF, Ferrer JC, Martínez M, Vayá A, Aznar J.
    Clin Hemorheol Microcirc; 2002 Apr 20; 27(3-4):193-9. PubMed ID: 12454376
    [Abstract] [Full Text] [Related]

  • 10. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S, Scruel O, Deckelbaum RJ, Dupont IE, Ducobu J, Carpentier YA.
    Int J Cardiol; 2005 Oct 10; 104(3):338-45. PubMed ID: 16186066
    [Abstract] [Full Text] [Related]

  • 11. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T.
    Clin Ther; 2007 Nov 10; 29(11):2419-32. PubMed ID: 18158082
    [Abstract] [Full Text] [Related]

  • 12. L-Arginine enhances the triglyceride-lowering effect of simvastatin in patients with elevated plasma triglycerides.
    Schulze F, Glos S, Petruschka D, Altenburg C, Maas R, Benndorf R, Schwedhelm E, Beil U, Böger RH.
    Nutr Res; 2009 May 10; 29(5):291-7. PubMed ID: 19555809
    [Abstract] [Full Text] [Related]

  • 13. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R, Mahajan M, Singh B, Bal BS, Kant R.
    J Indian Med Assoc; 2006 Sep 10; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [Abstract] [Full Text] [Related]

  • 14. Effects of simvastatin on plasma antioxidant status and vitamins in hypercholesterolemic patients.
    Shin MJ, Chung N, Lee JH, Jang Y, Park E, Jeon KI, Chung JH, Seo BY.
    Int J Cardiol; 2007 May 31; 118(2):173-7. PubMed ID: 17005272
    [Abstract] [Full Text] [Related]

  • 15. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging.
    Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Chaplin WF, Muntwyler J, Viles-Gonzalez JF, Weinberger J, Smith DA, Mizsei G, Badimon JJ.
    J Am Coll Cardiol; 2005 Jul 05; 46(1):106-12. PubMed ID: 15992643
    [Abstract] [Full Text] [Related]

  • 16. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients.
    Huang CY, Wu TC, Lin WT, Leu HB, Lin CP, Lin SJ, Chen JW.
    Eur J Clin Invest; 2006 Feb 05; 36(2):76-84. PubMed ID: 16436088
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T, Davidson M, Shah A, Maccubbin D, Meehan A, Zakson M, Tribble D, Veltri E, Mitchel Y.
    Clin Ther; 2006 Jun 05; 28(6):849-59. PubMed ID: 16860168
    [Abstract] [Full Text] [Related]

  • 18. Anti-inflammatory and hypolipemic effects in vitro of simvastatin comparing to epicatechin in patients with type-2 hypercholesterolemia.
    Franiak-Pietryga I, Koter-Michalak M, Broncel M, Duchnowicz P, Chojnowska-Jezierska J.
    Food Chem Toxicol; 2009 Feb 05; 47(2):393-7. PubMed ID: 19084570
    [Abstract] [Full Text] [Related]

  • 19. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA.
    Br J Clin Pract Suppl; 1994 Dec 05; (77):28-32. PubMed ID: 19496270
    [Abstract] [Full Text] [Related]

  • 20. Co-administration of ezetimibe and simvastatin in acute myocardial infarction.
    Chenot F, Montant PF, Marcovitch O, Blaimont M, de Meester A, Descamps OS.
    Eur J Clin Invest; 2007 May 05; 37(5):357-63. PubMed ID: 17461981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.